Greystone Financial Group’s VanEck Biotech ETF BBH Stock Holding History

Greystone Financial Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,966	Closed	-$306K	–	106
2023 Q3	$306K	Sell	1,966 -29	-1%	-$4.63K	0.08%	90
2023 Q2	$311K	Sell	1,995 -900	-31%	-$144K	0.07%	96
2023 Q1	$469K	Buy	+2,895	New	+$468K	0.12%	79

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

CIG

Consolidated Investment Group Englewood, Colorado $922M AUM 28.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Greystone Financial Group's BBH Position: Q4 2023 in Review

Greystone Financial Group sold out of VanEck Biotech ETF (BBH) in Q4 2023, closing a stake of 1,966 shares — an estimated $306K sold.

Greystone Financial Group first reported a position in BBH in Q1 2023 and held it in 3 quarters. The position peaked at $469K in Q1 2023. 116 funds tracked by Wall St. Rank hold BBH as of Q4 2023.

Greystone Financial Group reported no remaining VanEck Biotech ETF position as of Q4 2023 after selling out during the quarter.
Greystone Financial Group sold 1,966 VanEck Biotech ETF shares in Q4 2023, an estimated $306K.
Greystone Financial Group first reported a position in VanEck Biotech ETF in Q1 2023 and held it in 3 quarters.
Greystone Financial Group's VanEck Biotech ETF position peaked at $469K in Q1 2023.
116 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2023.

Based on Greystone Financial Group's 13F filing for Q4 2023, filed 14 Feb 2024.